fgf-1

Recombinant proteinexperimental

Clinical trial activity

8 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Sep 1, 2005 (NCT00425178)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • fgf-1
  • fgf-1 141
  • fibroblast growth factor-1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06516939N/AJun 10, 2024Shanghai Dermatology Hospital
NCT05493462Phase 1Sep 30, 2022Zhittya Genesis Medicine, Inc.
NCT04235868Phase 1Jan 20, 2020People's Liberation Army of China
NCT03229031Phase 3Mar 7, 2018Eusol
NCT00424866Phase 1Dec 1, 2014Department of Veteran Affairs, Venturis Therapeutics
NCT00916292Phase 1Nov 1, 2012Phage Pharmaceuticals, Inc.
NCT00117936Phase 2Sep 1, 2008Mercy Gilbert Medical Center, Venturis Therapeutics
NCT00425178Phase 1Sep 1, 2005Venturis Therapeutics, Warren General Hospital
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Venturis TherapeuticsFor profit3322005
Department of Veteran AffairsGovernment1012014
EusolFor profit1112018
Mercy Gilbert Medical CenterAcademic/Hospital1012008
People's Liberation Army of ChinaGovernment1112020
Phage Pharmaceuticals, Inc.For profit1112012
Shanghai Dermatology HospitalAcademic/Hospital1112024
Warren General HospitalAcademic/Hospital1012005
Zhittya Genesis Medicine, Inc.Academic/Hospital1112022
9 organizations
Page 1 / 1